Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Cancer Res Ther ; 18(3): 831-833, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35900568

RESUMEN

Cancer male breast is not very common. It comprises <1% of all breast cancers. Primary sites of metastasis are bone, brain, lung, and liver. Endobronchial and tracheal metastasis is very rare. To the best of our information, this is the first case of male breast carcinoma with upfront tracheal and endobronchial metastasis which presented as Superior vena cava obstruction (SVCO), initially evaluated on the lines of metastatic nonsmall-cell lung cancer. A 60-year-old gentleman presented with shortness of breath and features of SVCO. On primary evaluation, he was thought to be a case of nonsmall-cell lung cancer. Later on, it was confirmed to be carcinoma male breast with endobronchial and tracheal metastasis, which was reconfirmed with biopsy. The case we came across had symptoms associated with endobronchial metastases from primary extrapulmonary tumor and which was later found out to be breast. Treatment options are very different from lung primary and thus, we should be aware of the unusual disease presentation.


Asunto(s)
Neoplasias de la Mama Masculina , Carcinoma de Pulmón de Células no Pequeñas , Carcinoma , Neoplasias Pulmonares , Síndrome de la Vena Cava Superior , Neoplasias de la Mama Masculina/complicaciones , Neoplasias de la Mama Masculina/diagnóstico , Carcinoma/complicaciones , Carcinoma de Pulmón de Células no Pequeñas/complicaciones , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico , Humanos , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/diagnóstico , Masculino , Persona de Mediana Edad , Síndrome de la Vena Cava Superior/diagnóstico , Síndrome de la Vena Cava Superior/etiología , Vena Cava Superior
2.
J Biochem Mol Toxicol ; 35(8): e22820, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34075651

RESUMEN

Bisphenol S (BPS) is an organic chemical that has been used as a substitute for bisphenol A (BPA) in making polycarbonate plastics, epoxy resins, thermal receipt papers, and currency bills, as BPA has been reported to have dreadful effects on the living system. From this view point, the present study investigates whether BPS has the same or rather more toxic effects like BPA or not. Limited studies were carried out on the effect of BPS on fish. The hepatic antioxidant enzymes such as superoxide dismutase, catalase, glutathione S-transferase, glutathione reductase, and glutathione peroxidase (GPx), along with the nonenzymatic antioxidant, glutathione, in a freshwater fish, Labeo rohita, were selected as biomarkers. The results revealed that the sublethal exposure of BPS significantly influenced the activities of these biomarkers. Lipid peroxidation (LPO) products such as malondialdehyde and conjugate diene levels were also altered by the exposure. The alteration in the levels of antioxidants and LPO products after BPS exposure clearly showed that the fish experienced oxidative stress. Furthermore, the current study showed that BPS is a pollutant with oxidative potential by disrupting the antioxidant enzymes.


Asunto(s)
Cyprinidae/metabolismo , Estrés Oxidativo/efectos de los fármacos , Fenoles/toxicidad , Sulfonas/toxicidad , Xenobióticos/toxicidad , Animales
4.
Respir Med Case Rep ; 28: 100954, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31720204

RESUMEN

With the advent of targeted therapies there was a paradigm shift in the treatment of metastatic adenocarcinoma of lung. Immuno-histopathology and molecular subtyping in metastatic adenocarcinoma lung have enabled personalized treatment for each patient. Oncogenic driver mutations in non-small cell lung cancer are commonly EGFR (Epidermal Growth Factor Receptor) gene mutation and ALK (Anaplastic Lymphoma Kinase) gene rearrangement, which are mutually exclusive. Almost 60-64% patients have oncogenic mutation, which are mutually exclusive. Here, we present a case with EGFR mutation and ALK gene rearrangement which was expressed sequentially and with metastasis to rarest sites bilateral breast, ovaries and endometrium. Even though presented with upfront metastatic disease, patient was treated with multiple lines of targeted agents, by which patient survived for 5 years with good quality of life.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA